Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases
Yoichi Yoshida, Xiaomeng Zhang, Hao Wang, Toshio Machida, Seiichiro Mine, Eiichi Kobayashi, Akihiko Adachi, Tomoo Matsutani, Ikuo Kamitsukasa, Takeshi Wada, Akiyo Aotsuka, Katsuro Iwase, Go Tomiyoshi, Rika Nakamura, Natsuko Shinmen, Hideyuki Kuroda, Hirotaka Takizawa, Koichi Kashiwado, Hideo Shin, Yuichi Akaogi, Junichiro Shimada, Eiichiro Nishi, Mikiko Ohno, Minoru Takemoto, Koutaro Yokote, Kenichiro Kitamura, Yasuo Iwadate, Takaki Hiwasa
Abstract
BACKGROUND: Serum antibody markers have been increasingly identified not only for cancer and autoimmune diseases but also for atherosclerosis-related diseases such as acute ischemic stroke (AIS), acute myocardial infarction (AMI), diabetes mellitus (DM), and chronic kidney disease (CKD). Biomarkers for transient ischemic attack (TIA) and non-ST segment elevation acute coronary syndrome (NSTEACS) are potentially useful for detection of early phase of atherosclerotic changes against AIS and AMI, respectively. METHODS: We utilized serological identification of antigens by recombinant cDNA expression cloning (SEREX) using a human aortic endothelial cell cDNA phage library and sera from patients with TIA or NSTEACS. Serum antibody levels were measured by amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) using purified recombinant antigens. RESULTS: = 0.0005), respectively. Serum DNAJC2-Ab levels were also higher in patients with AMI, DM, and CKD than those in HDs. CONCLUSION: Serum DNAJC2-Ab level may be useful for early detection of atherosclerotic lesions, which lead to AIS and AMI.